Get the Stockscreener App
1.43
5.30%
-0.08
After Hours:
1.41
-0.02
-1.40%
Zentalis Pharmaceuticals Inc stock is traded at $1.43, with a volume of 545.61K.
It is down -5.30% in the last 24 hours and down -23.53% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$1.51
Open:
$1.5
24h Volume:
545.61K
Relative Volume:
0.37
Market Cap:
$97.66M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.315
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
+10.85%
1M Performance:
-23.53%
6M Performance:
-49.47%
1Y Performance:
-86.98%
1-Day Range:
$1.41
$1.505
1-Week Range:
$1.275
$1.565
52-Week Range:
$1.01
$13.24
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.43 | 97.66M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Zentalis Pharmaceuticals Inc (ZNTL) deserves deeper analysis - uspostnews.com
Chief Medical Officer Bruns Ingmar acquire 20,000 shares of Zentalis Pharmaceuticals Inc [ZNTL] - knoxdaily.com
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting - The Manila Times
Zentalis Pharmaceuticals Announces Poster Presentation at ASCO 2025 on Azenosertib for Colorectal Cancer - Nasdaq
New Clinical Data: Zentalis's Novel Cancer Drug Shows Promise in Metastatic Colorectal Cancer Treatment - Stock Titan
JPMorgan Chase & Co. Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Franklin Resources Inc. Buys Shares of 106,748 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Raymond James Financial Inc. Takes Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
12,840 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Acquired by Prudential Financial Inc. - Defense World
Sei Investments Co. Purchases Shares of 35,320 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL): Can The Stock Still Lose Despite An -61.39% YTD Loss? - Marketing Sentinel
Zentalis stock plunges to 52-week low at $1.08 amid market challenges - Investing.com Canada
Lost Money on Zentalis Pharmaceuticals, Inc.(ZNTL)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
ZNTL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire
Thrivent Financial for Lutherans Grows Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages - Defense World
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Zentalis Strengthens Team with $194,600 in Equity Incentives - Stock Titan
Virtu Financial LLC Buys Shares of 24,973 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Leerink Partnrs Issues Pessimistic Outlook for ZNTL Earnings - Defense World
What is HC Wainwright’s Forecast for ZNTL Q1 Earnings? - Defense World
Leerink Partnrs Has Pessimistic Outlook of ZNTL Q1 Earnings - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Position Lifted by Charles Schwab Investment Management Inc. - Defense World
Wedbush Reiterates Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals: Hold Rating Amid Clinical Progress and Financial Uncertainty - TipRanks
Bank of New York Mellon Corp Sells 10,375 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives “Buy” Rating from HC Wainwright - Defense World
Zentalis Pharmaceuticals Reports Progress and Financials - TipRanks
Stifel maintains Buy on Zentalis stock with $9 target By Investing.com - Investing.com Canada
H.C. Wainwright sets $10 target for Zentalis shares, maintains Buy By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates - The Manila Times
Zentalis Pharmaceuticals Inc Reports Annual EPS of -$2.33, Excee - GuruFocus
Zentalis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zentalis Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - Marketscreener.com
Zentalis Breakthrough: 35% Response Rate in Ovarian Cancer Trial Wins FDA Fast Track - Stock Titan
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Manila Times
Zentalis Pharmaceuticals to Present Multiple Posters at the - GlobeNewswire
Major Cancer Breakthrough: Zentalis Reveals New Azenosertib Data Across Multiple Tumor Types - Stock Titan
Zentalis Pharmaceuticals Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
Zentalis pharmaceuticals director Luke Walker buys $24,966 in stock - MSN
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Buy Rating from HC Wainwright - The AM Reporter
H.C. Wainwright maintains $10 target on Zentalis stock By Investing.com - Investing.com Canada
Zentalis Highlights Promising Azenosertib Data at SGO 2025 - TipRanks
Zentalis Pharmaceuticals Presents Updated Clinical Data at - GlobeNewswire
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - MarketScreener
Zentalis Announces Updated Clinical Data From Part 1b Of DENALI Trial Of Azenosertib In PROC - Nasdaq
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - TradingView
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Has Been Trading Down. What Are The Prospects For The Future? - stocksregister.com
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):